Dennis Harris has been appointed chief scientific officer of IntegenX, which makes automated genomic sample prep systems. Harris is a co-founder of IntegenX and has been a board member since 2003. Previously, he served as chief scientific officer of Millipore, and as chief scientific officer of Serologicals, which was acquired by Millipore. He has also held positions at Amersham International, where he developed products required for bead-based methods in automated DNA processing systems and for DNA sequencing; Amersham Pharmacia Biotech, where he served as the product manager for the first commercial capillary array-based DNA sequencing and genotyping product; and Aclara Biosciences.
Jay Shendure has joined Halo Genomics' scientific advisory board. Shendure is an assistant professor at the department of genome sciences at the University of Washington. He has helped develop a number of sequencing technologies, including polony sequencing, which formed the basis for Life Technologies' SOLiD sequencer, and his lab has helped develop the use of exome sequencing to solve the genetic basis of Mendelian disorders. Recently, he was named the Lowell Milken Prostate Cancer Foundation Young Investigator.
Olink Genomics has appointed a new chairman of the board and a chief business officer.
Mårten Winge has been named chairman of the board, replacing Mats Nilsson as of October 2010. Nilsson will remain a member of the board. Previously, Winge served as CEO of Proxeon A/S, a company acquired by Thermo Fisher Scientific. Winge has 20 years of biotech tools industry experience, holding marketing and sales positions at Amersham Biosciences; executive management positions at Pyrosequencing AB (now Qiagen), Olink AB, which he co-founded, and Cellectricon AB. Mårten holds an MS from the Karolinska Institute, Sweden.
Maria Hjortsmark has joined the company as its chief business officer. Previously, she was the senior brand manager at Phadia AB, which specializes in autoimmune disease diagnostics. Hjortsmark has over 20 years experience in product management, marketing and sales at companies such as Pharmacia Biotech and Pyrosequencing AB. She holds a BS in molecular biology from the University of Uppsala.
Timothy Triche has been appointed to WaferGen Biosystems' board of directors. Triche is the director of the center for personalized medicine at the Children's Hospital Los Angeles, and is working to develop a core facility that will implement next-gen sequencing on the Ion Torrent PGM to help with diagnosis and treatment decisions for childhood cancers (IS 12/14/2010). He replaces Nadine Smith, who served as a board member from 2008 until February 2011, when she resigned.
Triche has also served as the chief of the department of pathology and laboratory medicine at the Children's Hospital Los Angeles and as the section chief and head of molecular diagnostics in the laboratory of pathology at the National Cancer Institute. He holds a BS from Cornell University in physics and biology, and MD and PhD degrees from Tulane University.
Timothy Rink, former chairman of the board of directors of Solexa, has joined the therapeutic advisory board for aTyr Pharma. Rink is director of Kymab, Santhera Pharmaceuticals, and Stevenage Bioscience Catalyst. Previously, he was chairman of the Wellcome Trust Technology Transfer Strategy Panel, chairman and CEO of Aurora Biosciences, president and chief technical officer of Amylin Pharmaceuticals and vice president for research at SmithKline. He holds a doctor's of science, an MA, and an MD from the University of Cambridge.